Formerly known as Pharmatec, Pharmos Corporation was a bio-pharmaceutical company focused on the discovery, development and commercialization of therapeutics for the central and peripheral nervous systems, and ophthalmologic, cardiovascular and inflammation-related indications. On October 1992, the Company merged with Pharmos Corporation, a privately held New York corporation (âOld Pharmosâ), and in 1992 acquired all of the outstanding shares of Xenon Vision, Inc., a privately held Delaware corporation. Prior to the Merger, Old Pharmos was a biopharmaceutical company with proprietary drug delivery and formulation technologies, one of which involved an initial application of ophthalmic drugs, and another of which involved research pharmaceuticals with neuroprotective properties being developed for applications such as stroke and head trauma. Prior to the Merger, the Company was a publicly-held company primarily engaged in the development and testing of a chemical delivery system that had been shown in animal studies to permit the passage of drugs across the blood-brain barrier. Finally delisted from NASDAQ in 2014 due to too small number of people holding stco,, on the way the firm had many senior players in Executive positions, made several acqusitions and in a raft of transactions, raised a great deal of mo
